The complaint filed against GeneDx (NASDAQ: WGS) centers on a significant downturn in adjusted gross margins during the first quarter of 2026. According to the court filing, these performance issues forced the company to lower its full-year earnings projections, exposing a disconnect between the firm’s public disclosures and its actual financial trajectory. The lawsuit alleges that these omissions and statements violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Legal counsel from the DJS Law Group is currently soliciting shareholders who suffered losses during the specified class period. While the firm is seeking potential lead plaintiffs to represent the class, investors are reminded that such an appointment is not a prerequisite for participating in any future recovery. Interested parties have until August 3, 2026, to take action regarding their claims. The firm, led by David J. Schwartz, specializes in securities litigation and represents a portfolio of hedge funds and institutional asset managers.
Comments (0)
No comments yet. Be the first!